Option chain shows key data for Cannara Biotech's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Cannara Biotech.

Cannara Biotech (OTC:LOVFF) Stock, Option Chain

Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .

AI-Generated Image

Analyst Color

Cannabis

News

Guidance

Eurozone

Retail Sales

Global

Markets

Analyst Ratings

Trading Ideas

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CRON

DBCCF

LOVFF

TLRY

Beyond Canada, this global cannabis company is focused on its international business, particularly in Germany, Australia, and the UK.

Are You Missing Out On This NASDAQ-Listed Weed Stock? Low-Cost Model Meets European Demand

Market Summary

Penny Stocks

Small Cap Analysis

Financing

Small Cap

Decibel, a leading Canadian pre-roll franchise, may trade closer to larger market-cap cannabis stocks, according to analyst Pablo Zuanic.

Decibel Cannabis: One Acquisition Could Be The Key To Unlocking $20M In Cash Flow

elsa-olofsson-12-Zs1xIEtA-unsplash(25)

LOVE

TSXV:LOVE

Vertically integrated cannabis producer Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0) announced on Monday its fourth quarter and full fiscal 2024 financial and operating results ended Aug. 31. The Montreal, Canada-based company revealed a 43% year-over-year revenue growth in 2024 to CA$82.2 million ($58.8 million).  Gross profit for the full year grew by 32% over the same period, reaching CA$27.9 million, with a gross margin of 34% before fair value adjustments. Positive operating cash flow increased by 81% to CA$10.7 million, while free cash flow turned positive at CA$3.2 million, a CA$7.2 million turnaround from 2023.

Canadian Cannabis Producer Cannara Reports 43% YoY Revenue Growth, Boosts Market Share And Profitability

CANNARA BIOTECH INC by Cannara Biotech Inc.

Cannara Biotech Inc

Earnings

Press Releases

Cannara Biotech Reports Q2 2024 Financial Results

Cannara Biotech Reports Q3 2024 Financial Results

Cannara Biotech Achieves its Highest National Market Share of 3.2% in July 2024 and Announces Investor Webcast Scheduled for August 20, 2024

Cannara Biotech Inc. Reports Q4 and Fiscal Year 2024 Results: Achieves Record Sales Growth and Operating Cash Flow, Solidifying Leadership in Canada's Cannabis Market

Cannara Biotech to Host Investor Webcast on Thursday December 19th, 2024

Cannara Provides Update on Its 2024 Annual General Meeting Materials amid Canada Post Strike

Cannara Biotech Reports Record Q1 2025 Revenue and National Market Share, Sets Stage for Continued Momentum in 2025

Cannara Announces Extension of BMO Credit Facility and Convertible Debenture to Enhance Financial Flexibility and Support Execution of its Long-Term Strategy

Cannara Biotech to Present at The Ventum Canadian Cannabis Conference on March 12th, 2025

Management

Cannara Biotech Announces Appointment of Justin Cohen to Board of Directors

Cannara Biotech

Comments

Cannara Biotech

Cannara Biotech (LOVFF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga